Inhibition of the STAT3/Fanconi Anemia Axis Is Synthetic Lethal with PARP Inhibition in Breast Cancer

Utilizing a click chemistry strategy, researchers demonstrate that Nifuroxazide was a prodrug that was specifically bioactivated in breast CSCs.